Model of Relapsing Remitting MS that responds to Teriflunomide

Newsletter # 86


Relapsing forms of MS

Animal models

Teriflunomide (Aubagio®) is a disease-modifying immunomodulatory drug that inhibits de novo pyrimidine synthesis and thereby reduces lymphocyte proliferation and inflammation.

It was initially used to treat rheumatoid arthritis and was later approved for the treatment of multiple sclerosis . Indeed, several clinical evidences have shown the efficiency of Teriflunomide for the treatment of relapsing forms of MS without major safety concerns.

In the rat model of relapsing remitting MS run at NEUROFIT, Teriflunomide was found to fully suppress any sign of neurological disability.

  • Relapsing remitting form of MS is reproduced in experimental autoimmune encephalomyelitis in rats (RR-EAE)
    following immuzation with a homologous spinal cord homogenate.

  • Signs of neurological symptom
  • After 8 days, the first sign of neurological symptom is observed (red curve).
    The peak of disability occurs around day 13 which is immediately followed by a spontaneous remission.
    A disease relapse appears after about 18 days with a peak around day 21-22.

    Daily oral Teriflunomide (10 mg/kg) initiated at the time of symptom onset (Day 8) fully prevents the occurrence of any significant disease disability (blue curve).
  • We look forward to hearing from you.


NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us. Privacy Policy
On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please sign up on our mailing list: